Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial

By afschroeder • February 7, 2026

Landon BV, Boland JL, Wahner Hendrickson AE, Armstrong DK, Winterhoff B, Wehr J, Annapragada AV, Cherry C, Balan A, Kaleka G, Velculescu VE, Baylin SB, Zahnow CA, Slamon DJ, Konecny GE, Anagnostou V, Glaspy JA. Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial. Commun Med (Lond). 2026 Feb 6. doi: 10.1038/s43856-026-01404-0. Epub ahead of print. PMID: 41652014.

Tags: Fellow, Hematology/Oncology, Olive View DoM, Publications

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML

Borate UM, Huang Y, Lin TL, Handa S, Swords R, Lachowiez CA, Traer E, Stock W, Odenike O, Patel AA, Baer MR, Duong VH, Stein[...]

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004

Wierda WG, Dorritie KA, Gauthier J, Nath R, Kipps TJ, Riedell PA, Eradat HA, Kenderian SS, Kharfan-Dabaja MA, Shah NN, Solomon SR, Stephens DM, Ermann[...]

Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis